Welcome to LookChem.com Sign In|Join Free

CAS

  • or

10330-59-3

Post Buying Request

10330-59-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

10330-59-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 10330-59-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,3,3 and 0 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 10330-59:
(7*1)+(6*0)+(5*3)+(4*3)+(3*0)+(2*5)+(1*9)=53
53 % 10 = 3
So 10330-59-3 is a valid CAS Registry Number.

10330-59-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-methyl-1-pyridin-2-ylbutan-2-one

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:10330-59-3 SDS

10330-59-3Relevant articles and documents

-

Komin,Wolfe

, p. 2481,2482,2484 (1977)

-

Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists

Nirogi, Ramakrishna,Mohammed, Abdul Rasheed,Shinde, Anil K.,Gagginapally, Shankar Reddy,Kancharla, Durga Malleshwari,Middekadi, Vanaja Reddy,Bogaraju, Narsimha,Ravella, Srinivasa Rao,Singh, Pooja,Birangal, Sumit Raosaheb,Subramanian, Ramkumar,Palacharla, Raghava Choudary,Benade, Vijay,Muddana, Nageswararao,Jayarajan, Pradeep

, p. 4993 - 5008 (2018/05/29)

Alzheimer's disease (AD) is a neurodegenerative disorder that has a higher prevalence and incidence in people older than 60 years. The need for improved AD therapies is unmet as the current therapies are symptomatic with modest efficacy. Partial agonists of the 5-HT4 receptor (5-HT4R) offer both symptomatic and disease-modifying treatments as they shift amyloid-precursor-protein (APP) processing from the amyloidogenic pathway to the nonamyloidogenic pathway by activating the α-secretase enzyme. In addition, they also offer symptomatic treatment by increasing levels of the neurotransmitter acetylcholine in the brain. Because of this fascinating dual mechanism of action, several chemical scaffolds having 5-HT4R pharmacophores were designed and evaluated. Most of the synthesized compounds showed potent in vitro affinities and in vivo efficacies. Upon analysis of focused structure-activity relationships, compound 4o was identified as a potent 5-HT4R partial agonist with favorable ADME properties and good in vivo efficacy. GR-125487, a selective 5-HT4R antagonist, attenuated the activity of compound 4o in the novel-object-recognition-test cognition model.

2-Pyridinyl β-ketones as new ligands for roomerature CuI-catalysed C-N coupling reactions

Wang, Deping,Ding, Ke

supporting information; experimental part, p. 1891 - 1893 (2009/10/23)

2-Pyridinyl β-ketones were identified as new efficient ligands for CuI-catalysed N-arylation of aliphatic amines at room temperature with great selectivity and substrate scope tolerance.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 10330-59-3